Single Patient Safety Concern Hits Allogene’s Off-The-Shelf CAR-T
All Of Company’s Trials Halted
Allogene is the frontrunner in the allogeneic CAR-T field but must assess whether or not its therapy could have caused a patient’s unexpected chromosomal abnormality.
You may also be interested in...
Allogene hopes its off-the-shelf CAR-T can begin a potentially pivotal Phase II study by the end of this year but is frustrated by an “under-resourced and overworked FDA.”
The company is winding down its autologous myeloma CAR-T program as competition in that market heats up and interest in off-the-shelf CAR-Ts grows.
The King's College London spin-out has gained £11.5m backing to take its ‘parallel CAR-T’ into the clinic.